ArticleNeuroImage. Clinical2017
Longitudinal evaluation of cerebral and spinal cord damage in Amyotrophic Lateral Sclerosis.
Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Quantification of amyotrophic lateral sclerosis (ALS) disease accumulation with T1-weighted high-resolution magnetic resonance imaging: validation in an independent cohort.Journal of neurology · 2026Article
- Mapping motor and extra-motor gray and white matter changes in ALS: a comprehensive review of MRI insights.Neuroradiology · 2025Review
- Body size and intracranial volume interact with the structure of the central nervous system: A multi-center in vivo neuroimaging study.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- SynSpine: an automated workflow for the generation of longitudinal spinal cord synthetic MRI data.Frontiers in neuroinformatics · 2025Article
- Review
- Analysis of brain and spinal MRI measures in a common domain to investigate directional neurodegeneration in motor neuron disease.Journal of neurology · 2023Article
- Cervical spinal cord atrophy in amyotrophic lateral sclerosis across disease stages.Annals of clinical and translational neurology · 2023Article
- The confound of hemodynamic response function variability in human resting-state functional MRI studies.Frontiers in neuroscience · 2023Article
- Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.Muscle & nerve · 2022Article
- Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis.Human brain mapping · 2022Article
- Generic acquisition protocol for quantitative MRI of the spinal cord.Nature protocols · 2021Article
- Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model.Human brain mapping · 2021Article
- Feature selection from magnetic resonance imaging data in ALS: a systematic review.Therapeutic advances in chronic disease · 2021Review
- Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis.NeuroImage. Clinical · 2021Article
- A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS.Neurology · 2020Article
- Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy.Journal of inherited metabolic disease · 2020Article
- Connectome-Based Propagation Model in Amyotrophic Lateral Sclerosis.Annals of neurology · 2020Article
- The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI.Scientific reports · 2020Article
- Multimodal MRI Longitudinal Assessment of White and Gray Matter in Different SPG Types of Hereditary Spastic Paraparesis.Frontiers in neuroscience · 2020Article
- Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis.NeuroImage. Clinical · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate MRI-based parameters as biomarkers of Amyotrophic Lateral Sclerosis (ALS) progression.
methodsTwenty-seven patients and 27 controls performed two clinical and MRI acquisitions 8 months apart. ALSFRS-R scale was used to quantify disease severity at both time points. Multimodal analyses of MRI included cortical thickness measurements (FreeSurfer software), analysis of white matter integrity using diffusion-tensor imaging (tract-based spatial statistics-TBSS) and measurement of cervical spinal cord cross-sectional area (SpineSeg software). All analyses were corrected for multiple comparisons. The standardized response mean (SRM = mean score change / standard deviation of score change) was calculated for all methods herein employed and used for comparison purposes.
resultsThere were 18 men and mean age at first examination was 51.9 years. Mean ALSFRS-R scores at baseline and follow-up were 34.0 and 29.0, respectively. There was no region with progressive cortical thinning, but there was significant brainstem volumetric reduction (p = 0.001). TBSS analyses revealed progressive increase of AD (axial diffusivity) and MD (mean diffusivity) at the corpus callosum (p < 0.05), whereas SpineSeg showed progressive cord area reduction (p = 0.002). Cervical spinal cord cross-sectional area reduction was the only MRI parameter that correlated with ALSFRS-R change (r = 0.309, p = 0.038). SRM for ALSFRS-R was 0.95, for cord area 0.95, for corpus callosum AD 0.62 and MD 0.65, and for brainstem volume 0.002.
conclusionsStructural MRI is able to detect short term longitudinal changes in ALS. Cervical spinal cord morphometry is a promising neuroimaging marker to assess ALS course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.